Omeros eyes up 2014 launch for ophthalmic agent but what’s the opportunity?
This article was originally published in Scrip
Executive Summary
Omeros Corporation continues to stay on track with planned US and EU submissions for its ophthalmology product, OMS302, in the first half of next year and mid-2013 respectively, after reporting positive data from a second pivotal Phase III trial of the agent. The company is hoping for market launches in 2014.